Cargando…
Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
Next-generation sequencing (NGS), also known as massively parallel sequencing, is rapidly being incorporated into oncology practice. Interpretation of genomic reports and selecting treatments based on the tumor's genomic analysis becomes more and more complicated for the treating oncologist bec...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880252/ https://www.ncbi.nlm.nih.gov/pubmed/29212833 http://dx.doi.org/10.1101/mcs.a001578 |
_version_ | 1783311131729723392 |
---|---|
author | Dumbrava, Ecaterina Ileana Meric-Bernstam, Funda |
author_facet | Dumbrava, Ecaterina Ileana Meric-Bernstam, Funda |
author_sort | Dumbrava, Ecaterina Ileana |
collection | PubMed |
description | Next-generation sequencing (NGS), also known as massively parallel sequencing, is rapidly being incorporated into oncology practice. Interpretation of genomic reports and selecting treatments based on the tumor's genomic analysis becomes more and more complicated for the treating oncologist because of the use of larger panels covering dozens to hundreds of genes and the amount of rapidly emerging clinical/translational data. To help guide personalized treatments in oncology, The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center has developed a knowledge base, available at https://personalizedcancertherapy.org or https://pct.mdanderson.org (PCT). This knowledge base provides information on the function of common genomic alterations and their therapeutic implications. Here, we describe how such genomic information can be used by health-care providers to identify genomically matched therapies. |
format | Online Article Text |
id | pubmed-5880252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Cold Spring Harbor Laboratory Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58802522018-04-13 Personalized cancer therapy—leveraging a knowledge base for clinical decision-making Dumbrava, Ecaterina Ileana Meric-Bernstam, Funda Cold Spring Harb Mol Case Stud Commentary Next-generation sequencing (NGS), also known as massively parallel sequencing, is rapidly being incorporated into oncology practice. Interpretation of genomic reports and selecting treatments based on the tumor's genomic analysis becomes more and more complicated for the treating oncologist because of the use of larger panels covering dozens to hundreds of genes and the amount of rapidly emerging clinical/translational data. To help guide personalized treatments in oncology, The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center has developed a knowledge base, available at https://personalizedcancertherapy.org or https://pct.mdanderson.org (PCT). This knowledge base provides information on the function of common genomic alterations and their therapeutic implications. Here, we describe how such genomic information can be used by health-care providers to identify genomically matched therapies. Cold Spring Harbor Laboratory Press 2018-04 /pmc/articles/PMC5880252/ /pubmed/29212833 http://dx.doi.org/10.1101/mcs.a001578 Text en © 2018 Dumbrava and Meric-Bernstam; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited. |
spellingShingle | Commentary Dumbrava, Ecaterina Ileana Meric-Bernstam, Funda Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title | Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title_full | Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title_fullStr | Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title_full_unstemmed | Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title_short | Personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
title_sort | personalized cancer therapy—leveraging a knowledge base for clinical decision-making |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880252/ https://www.ncbi.nlm.nih.gov/pubmed/29212833 http://dx.doi.org/10.1101/mcs.a001578 |
work_keys_str_mv | AT dumbravaecaterinaileana personalizedcancertherapyleveragingaknowledgebaseforclinicaldecisionmaking AT mericbernstamfunda personalizedcancertherapyleveragingaknowledgebaseforclinicaldecisionmaking |